BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $7.60 Consensus Target Price from Brokerages
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has been given an average rating of “Buy” by the eleven ratings firms that are covering the stock, MarketBeat reports. Five analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $8.17.
BCRX has been the topic of several research analyst reports. Zacks Investment Research lowered shares of BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, May 22nd. BidaskClub downgraded BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, June 2nd. JMP Securities upped their price target on BioCryst Pharmaceuticals from $10.00 to $11.00 and gave the stock an “outperform” rating in a research note on Friday. Needham & Company LLC reiterated a “hold” rating on shares of BioCryst Pharmaceuticals in a report on Wednesday, May 6th. Finally, Piper Sandler reissued a “buy” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Monday, June 8th.
Institutional investors have recently modified their holdings of the company. Legal & General Group Plc lifted its holdings in shares of BioCryst Pharmaceuticals by 6.7% in the first quarter. Legal & General Group Plc now owns 41,327 shares of the biotechnology company’s stock valued at $83,000 after purchasing an additional 2,602 shares in the last quarter. Rhumbline Advisers lifted its stake in BioCryst Pharmaceuticals by 2.5% during the 1st quarter. Rhumbline Advisers now owns 188,708 shares of the biotechnology company’s stock valued at $377,000 after acquiring an additional 4,539 shares in the last quarter. Victory Capital Management Inc. lifted its stake in BioCryst Pharmaceuticals by 50.0% during the 4th quarter. Victory Capital Management Inc. now owns 25,927 shares of the biotechnology company’s stock valued at $74,000 after acquiring an additional 8,646 shares in the last quarter. Bank of Montreal Can boosted its holdings in BioCryst Pharmaceuticals by 86.6% during the 4th quarter. Bank of Montreal Can now owns 19,898 shares of the biotechnology company’s stock worth $68,000 after acquiring an additional 9,236 shares during the last quarter. Finally, ProShare Advisors LLC grew its stake in shares of BioCryst Pharmaceuticals by 25.8% in the 4th quarter. ProShare Advisors LLC now owns 53,393 shares of the biotechnology company’s stock worth $184,000 after acquiring an additional 10,952 shares in the last quarter. 79.53% of the stock is owned by hedge funds and other institutional investors.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.24). The firm had revenue of $4.82 million for the quarter, compared to analysts’ expectations of $2.71 million. BioCryst Pharmaceuticals had a negative return on equity of 4,223.68% and a negative net margin of 241.66%. Equities research analysts anticipate that BioCryst Pharmaceuticals will post -0.95 earnings per share for the current year.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.
Featured Story: volatile stocks
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.